{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:06:56Z","timestamp":1774897616715,"version":"3.50.1"},"posted":{"date-parts":[[2024,1,25]]},"group-title":"Epidemiology","reference-count":29,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are few data on the real-world effectiveness of COVID-19 vaccines and boosting in Africa, which experienced high levels of SARS-CoV-2 infection in a mostly vaccine-na\u00efve population, and has limited vaccine coverage and competing health service priorities. We assessed the association between vaccination and severe COVID-19 in the Western Cape, South Africa.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed an observational cohort study of &gt;2 million adults during 2020-2022. We described SARS-CoV-2 testing, COVID-19 outcomes, and vaccine uptake over time. We used multivariable cox models to estimate the association of BNT162b2 and Ad26.COV2.S vaccination with COVID-19-related hospitalisation and death, adjusting for demographic characteristics, underlying health conditions, socioeconomic status proxies and healthcare utilisation.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>By end 2022, only 41% of surviving adults had completed vaccination and 8% a booster dose, despite several waves of severe COVID-19. Recent vaccination was associated with notable reductions in severe COVID-19 during distinct analysis periods dominated by Delta, Omicron BA.1\/2 and BA.4\/5 (sub)lineages: within 6 months of completing vaccination or boosting, vaccine effectiveness was 46-92% for death (range across periods), 45-92% for admission with severe disease or death, and 25-90% for any admission or death. During the Omicron BA.4\/5 wave, within 3 months of vaccination or boosting, BNT162b2 and Ad26.COV2.S were each 84% effective against death (95% CIs: 57-94 and 49-95, respectively). However, there were distinct reductions of VE at larger times post completing or boosting vaccination.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Continued emphasis on regular COVID-19 vaccination including boosting is important for those at high risk of severe COVID-19 even in settings with widespread infection-induced immunity.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.01.24.24301721","type":"posted-content","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T16:15:13Z","timestamp":1706199313000},"source":"Crossref","is-referenced-by-count":1,"title":["COVID-19 vaccine uptake and effectiveness by time since vaccination in the Western Cape province, South Africa: An observational cohort study during 2020-2022"],"prefix":"10.64898","author":[{"given":"Reshma","family":"Kassanjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Ann","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Heekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Mahomed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J","family":"Hawkridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milani","family":"Wolmarans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erna","family":"Morden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theuns","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Moultrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Lessells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette Van","family":"Der Walt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanita O","family":"Arendse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Goeiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Mudaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibongile","family":"Walaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waasila","family":"Jassat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"von Gottberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick L","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petro","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Feikin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Cloete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Boulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024012823450596000_2024.01.24.24301721v1.1","doi-asserted-by":"crossref","unstructured":"Wise J . COVID-19: WHO declares end of global health emergency. BMJ 2023;381:p1041.","DOI":"10.1136\/bmj.p1041"},{"key":"2024012823450596000_2024.01.24.24301721v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00801-5"},{"key":"2024012823450596000_2024.01.24.24301721v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0"},{"key":"2024012823450596000_2024.01.24.24301721v1.4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.10650"},{"key":"2024012823450596000_2024.01.24.24301721v1.5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","article-title":"Population immunity and COVID-19 severity with Omicron variant in South Africa","volume":"386","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"2024012823450596000_2024.01.24.24301721v1.6","doi-asserted-by":"crossref","unstructured":"Hussey H , Vreede H , Davies M-A , et al. Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa. medRxiv 2022:2022.12.01.22282927.","DOI":"10.1101\/2022.12.01.22282927"},{"key":"2024012823450596000_2024.01.24.24301721v1.7","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/S2214-109X(21)00563-5","article-title":"COVID-19 vaccine hesitancy in Africa: a call to action","volume":"10","year":"2022","journal-title":"The Lancet Global health"},{"key":"2024012823450596000_2024.01.24.24301721v1.8","doi-asserted-by":"crossref","first-page":"e26036","DOI":"10.1002\/jia2.26036","article-title":"Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium","volume":"25","year":"2022","journal-title":"Journal of the International AIDS Society"},{"key":"2024012823450596000_2024.01.24.24301721v1.9","doi-asserted-by":"crossref","first-page":"e1046","DOI":"10.1093\/cid\/ciab951","article-title":"Effects of the Coronavirus Disease 2019 Pandemic on Human Immunodeficiency Virus Services: Findings from 11 Sub-Saharan African Countries","volume":"75","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"2024012823450596000_2024.01.24.24301721v1.10","first-page":"448","article-title":"Impact of the COVID-19 pandemic on use of HIV care","volume":"88","year":"2021","journal-title":"Antiretroviral therapy adherence, and viral suppression: An observational cohort study from Uganda. JAIDS"},{"key":"2024012823450596000_2024.01.24.24301721v1.11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/cid\/ciab379","article-title":"Transient reductions in Human Immunodeficiency Virus (HIV) clinic attendance and food security during the Coronavirus Disease 2019 (COVID-19) pandemic for people living with HIV in 4 African countries","volume":"73","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"2024012823450596000_2024.01.24.24301721v1.12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMc2210093","article-title":"Effectiveness and durability of the BNT162b2 vaccine against Omicron sublineages in South Africa","volume":"387","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"2024012823450596000_2024.01.24.24301721v1.13","doi-asserted-by":"crossref","unstructured":"Boulle A , Heekes A , Tiffin N , et al. Data Centre Profile: The Provincial Health Data Centre of the Western Cape Province, South Africa. International Journal of Population Data Science 2019;4.","DOI":"10.23889\/ijpds.v4i2.1143"},{"key":"2024012823450596000_2024.01.24.24301721v1.14","unstructured":"Department of Health, Republic of South Africa. COVID-19 Online Resource and New Portal: Latest Vaccine Statistics. [Accessed 31 December 2023, at https:\/\/sacoronavirus.co.za\/latest-vaccine-statistics]."},{"key":"2024012823450596000_2024.01.24.24301721v1.15","unstructured":"National Institute for Communicable Diseases. COVID-19 Surveillance Reports. [Accessed 13 October 2023 at https:\/\/www.nicd.ac.za\/diseases-a-z-index\/disease-index-covid-19\/surveillance-reports]."},{"key":"2024012823450596000_2024.01.24.24301721v1.16","doi-asserted-by":"crossref","unstructured":"Jassat W , Karim S , Mudara C , et al. Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicron-dominant fourth wave. Lancet preprints 2021.","DOI":"10.2139\/ssrn.3996320"},{"key":"2024012823450596000_2024.01.24.24301721v1.17","doi-asserted-by":"crossref","first-page":"e1216","DOI":"10.1016\/S2214-109X(21)00289-8","article-title":"Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study","volume":"9","year":"2021","journal-title":"The Lancet Global health"},{"key":"2024012823450596000_2024.01.24.24301721v1.18","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases SA. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clinical Infectious Diseases 2020;73:e2005-e15."},{"key":"2024012823450596000_2024.01.24.24301721v1.19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/tmi.13752","article-title":"Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa","volume":"27","year":"2022","journal-title":"Trop Med Int Health"},{"key":"2024012823450596000_2024.01.24.24301721v1.20","doi-asserted-by":"crossref","unstructured":"Carazo S , Skowronski DM , Brisson M , et al. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. Lancet Infect Dis 2023;23:45-55.","DOI":"10.1016\/S1473-3099(22)00578-3"},{"key":"2024012823450596000_2024.01.24.24301721v1.21","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/infdis\/jiac161","article-title":"Protection by vaccines and previous infection against the Omicron variant of Severe Acute Respiratory Syndrome Coronavirus 2","volume":"226","year":"2022","journal-title":"J Infect Dis"},{"key":"2024012823450596000_2024.01.24.24301721v1.22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic Omicron infections","volume":"387","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"2024012823450596000_2024.01.24.24301721v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00288-2"},{"key":"2024012823450596000_2024.01.24.24301721v1.24","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rk J , Bonander C , Moghaddassi M , et al. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022. Euro Surveill 2022;27.","DOI":"10.2807\/1560-7917.ES.2022.27.18.2200322"},{"key":"2024012823450596000_2024.01.24.24301721v1.25","doi-asserted-by":"crossref","unstructured":"Madhi SA , Kwatra G , Myers JE , et al. South African population immunity and severe COVID-19 with Omicron variant. medRxiv 2021:2021.12.20.21268096.","DOI":"10.1101\/2021.12.20.21268096"},{"key":"2024012823450596000_2024.01.24.24301721v1.26","doi-asserted-by":"crossref","unstructured":"Plumb ID , Feldstein LR , Barkley E , et al. Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022;71:549-55.","DOI":"10.15585\/mmwr.mm7115e2"},{"key":"2024012823450596000_2024.01.24.24301721v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.006"},{"key":"2024012823450596000_2024.01.24.24301721v1.28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.7196\/SAMJ.2022.v112i3.16384","article-title":"Change in profile of COVID-19 deaths in Western Cape Province, South Africa, during the fourth wave","volume":"112","year":"2022","journal-title":"South African Medical Journal"},{"key":"2024012823450596000_2024.01.24.24301721v1.29","unstructured":"UK Health Security Agency. Changes to the way we report on COVID-19 deaths [Accessed 8 January 2024, at https:\/\/ukhsa.blog.gov.uk\/2023\/01\/27\/changes-to-the-way-we-report-on-covid-19-deaths]."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.01.24.24301721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:49:33Z","timestamp":1768506573000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.01.24.24301721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1101\/2024.01.24.24301721","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.3390\/vaccines12060628","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,1,25]]},"subtype":"preprint"}}